Astrazeneca Ab

Cadent Therapeutics, Inc.

Novartis Ag

Yale University

Timothy Piser

Robert A Volkmann

David R Anderson

Gregg F Keaney

Sam Malekiani

Steven C Leiser

Bernard Christophe Barlaam

Eifion D Phillips

Rebecca Urbanek

James Woods

James Jeffrey Folmer

Thomas Richard Simpson

Hui-Fang Chang

Dan Widzowski

Richard Alan Keith

Thomas Hudzik

Michael Thaddeus Klimas

Christopher Holmquist

Hui Xiong

Stacy A Castner

Donna L Maier

Ladislav Mrzljak

Graham V Williams

Jeff S Smith

Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.

Heteroaromatic NMDA receptor modulators and uses thereof

Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, Rand Rare as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.

Nicotinic acetylcholine receptor ligands 101

A method for treating a disease associated with the estrogen receptor-&#x3b2;, comprising the step of administiering a therapeutically-effective amount of a compound that satifies the equation: K/K&#x3e;25, optionally having general structure (I).

Estrogen receptor-&#x3b2; ligands

A method for treating a disease associated with the estrogen receptor-&bgr;, comprising the step of administering a therapeutically-effective amount of a compound that satisfies the equation: (K &agr; /Ki&bgr; )/(K &agr; /K &bgr; )>1, optionally having the general structure (I).

Estrogen receptor-&bgr; ligands

Method for treating neurological disorders

Growing community of inventors

Wilmington, DE, United States of America

Timothy Piser